Page 415 - Read Online

Page 3 of 36 J Cancer Metastasis Treat 2019;5:31 I http://dx.doi.org/10.20517/2394-4722.2019.21

All topics are presented with illustrated and labeled pictures of the various kinds of parasites and their
gross pathology in human tissues, when applicable. The presentation is followed by a brief discussion of
case histories as tested by us at PCI as well as by a treatment of intestinal pathogenic bacteria, also tested by
us, that usually cause GI symptoms similar to those caused by intestinal parasites.

3. The new oncological theory and its importance in the war with cancer

Andrei P. Kozlov

Biomedical Center, Peter the Great St.Petersburg Polytechnic University and Research Institute of Pure
Biopreparation, St. Petersburg 195251, Russia.

Earlier I formulated the concept of the possible evolutionary role of tumors (A.P. Kozlov, “Evolution by
Tumor Neo functionalization”, Elsevier/Academic Press, 2014). This concept suggests that heritable tumors
at earlier stages of progression supply evolving multicellular organisms with extra cell masses for the
expression of newly evolving genes. After expression of novel genes in tumor cells, tumors differentiate in
new directions and give rise to new cell types, tissues and organs.

In the presentation, the bulk of data supporting the positive evolutionary role of tumors will be reviewed,
obtained both in the lab of the author and from the literature sources. The new concept supports the
possibility of sustaining a stable tumor mass as a strategy in cancer therapy.

As a result of experimental confirmation of nontrivial predictions of the new concept a new class of genes
- Tumor Specifically Expressed, Evolutionarily New (TSEEN) genes - was discovered. Examples of TSEEN
genes will be presented. TSEEN genes may represent the new targets in the war with cancer.

4. Discovery of a novel PRMT5 inhibitor to treat pancreatic and colorectal cancers

Tao Lu

Department of Pharmacology and Toxicology, Indiana University School of Medicine, 635 Barnhill Drive,
Indianapolis, IN 46202, USA.

Recently, we disocvered that protein arginine methyltransferase 5 (PRMT5) functions as a novel activator
of the nuclear factor κB (NF-κB), a culprit in pancreatic ductal adenocarcinoma (PDAC) and colorectal
cancer (CRC). In this study, we adapted the AlphaLISA technique into a PRMT5-specific high throughput
screen, and discovered PR5-LL-CM01 as a novel small molecule inhibitor of NF-κB. Treatment of PDAC
and CRC cells with PR5-LL-CM01 inhibited tumor cell proliferation, anchorage-independent growth, as
well as cell migration. Furthermore, PR5-LL-CM01 greatly impeded tumor growth in PDAC and CRC
in vivo xenograft models. Importantly, PR5-LL-CM01 exhibited more potent anti-tumor effect than the
commercial PRMT5 inhibitor, EPZ015666, in both PDAC and CRC. Our study has established PR5-LL-
CM01 as a potential basis for novel drug development to treat PDAC and CRC in the future.

Biography
Dr. Tao Lu is a tenure-track Assistant Professor and principle investigator at Department of Pharmacology
and Toxicology, and a member of Simon Cancer Center at Indiana University School of Medicine. She